Tadashi Watabe

Associate Professor Osaka University

Prof. Tadashi Watabe is an Associate Professor at the University of Osaka, Japan and a board-certified nuclear medicine physician internationally recognized for advancing theranostics and targeted alpha therapy. He leads investigator-initiated first-in-human clinical trials using astatine-211, including the completed Alpha-T1 trial of [211At]NaAt for radioiodine-refractory thyroid cancer and the ongoing Alpha-PS1 trial of [211At]PSMA-5 for castration-resistant prostate cancer. He also directs clinical studies of emerging PET tracers, including FAPI-74, FBPA, and HCA2969. With more than 180 peer-reviewed publications, his research spans translational radiopharmaceutical development from preclinical innovation to clinical implementation. He serves as Executive Congress Chair of Theranostics World Congress 2027.

Seminars

Wednesday 24th February 2027
Translating Astatine-211 Targeted Alpha Therapy From Preclinical Development to First-in-Human Studies
5:00 pm
  • Translate novel At-211 compounds from discovery through preclinical development, examining the studies required to build confidence ahead of clinical translation
  • Navigate preclinical toxicity & translational considerations when progressing an At- 211 program towards FIH evaluation
  • Share lessons from investigator-initiated Phase I development to identify what early-stage RLT developers should consider when designing the next generation of alpha-emitting therapeutics

Novel Target

Tadashi Watabe, Speaker at 3rd TRP Target Selection & Drug Design Summit